abstract |
The present invention relates to a combination therapy comprising an effective amount of immune checkpoint molecular modulator and an effective amount of MDM2 inhibitor, wherein the MDM2 inhibitor is represented by the following formula: , Or a pharmaceutically acceptable salt thereof. |